Single-Use Assemblies Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Single-Use Assemblies Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The single-use assemblies market is projected to register a CAGR of 19.9% during the forecast period (2021-2026).

There is a significant impact of COVID 19 on the single-use assemblies’ market as there is growing adoption of single-use technology for research activities in COVID vaccine development. Many players are focusing on R&D activities for the development of a vaccine that requires single-use assemblies, and the suppliers are struggling to keep up with demand during the pandemic, thereby propelling the market growth of single-use assemblies.

Factors that are driving the market growth include rapid and easy implementation accompanied by a low risk of cross-contamination and an increase in R&D investment by biopharmaceutical companies. Single-use assemblies emerged in the global biopharmaceutical community as the cross-contamination hazards are decreased, cleaning procedures are simplified, and can get customized solutions. This helps in accelerating drug development and the manufacturing process.

Single-use assemblies have various advantages over traditional processes. Traditional processes can often lead to cross-contamination and leakage might occur. If the connections between the various components aren't formed correctly, it causes production delays. A leak or a risk to the process's product integrity might result in lost batches, which can be exceedingly costly for many end-users. Whereas single-use assemblies have reduced the risk of cross-contamination and leaks, eliminates cleaning and downtime, maintains quality and documentation control, increased efficiency, reduced labor, expense, and time for end-user, are easy to implement, reduced water and energy among others.

Increased R&D investment by biopharmaceutical companies is also contributing to the growth of the single-use assemblies market. In the last two decades, both R&D spending and the introduction of new drugs have been increased. For instance, as per the Congressional Budget Office, a federal agency within the legislative branch of the United States government that provides budget and economic information to Congress, the pharmaceutical sector spent 83 billion USD on research and development in 2019. Therefore, the advantages of single-use assemblies over traditional processes, along with increased biopharmaceutical R&D activities are propelling the market growth.

Key Market TrendsBio pharmaceutical & Pharmaceutical Companies Segment Accounted For The Largest Share of The Single-Use Assemblies Market

Biopharmaceutical and Pharmaceutical Companies extensively use single-use assemblies and consumables including aseptic bottle transfers, single-use manifolds, and custom tube kits to streamline the upstream process. The amount of money spent on research and development by biopharmaceutical and pharmaceutical firms has increased up to a large extent. According to Congressional Budget Office, a federal agency in the United States, pharmaceutical firms spent around one-quarter of their sales on R&D spending in 2019, which is near twice as much as they spent in 2000.

From 2000 through 2019, the Food and Drug Administration (FDA) approved an average of 38 new medicines each year (with a increase of 59 in 2019), which is 60% higher than the previous decade's average. Many of the medicines authorized in recent years have been classified as specialty pharmaceuticals. Specialty medicines are used to treat chronic, complicated, or uncommon diseases, and they may need specific patient management or monitoring. Many specialty medicines are biologics (large-molecule drugs based on living cell lines), which are expensive to produce, difficult to duplicate, and have a high price tag.

As a result, biopharmaceutical companies are putting a greater emphasis on creating low-cost biologics. For instance, According to the report launched by the Department of Biotechnology in 2019, Indian biopharmaceutical companies hold the lead with over 98 biosimilars authorized as of September 2019. Single-use assemblies offer a wide range of applications in each stage of the manufacturing process, and their use is growing extensively with the rise in biologics and biosimilars production. Below is a graph showing the average number of pharmaceutical drugs approved by FDA per year.

North America Holds the Major Share in the Single-Use Assemblies Market

The market for single-use assemblies is dominated by North America. The region's high share of the market is due to its well-established biopharmaceutical sector, widespread availability of single-use assemblies supplied by regional market leaders, and rising biologics and biosimilars manufacturing.

As per the International Trade Administration (ITA), managed by the U.S. Department of Commerce to promote and facilitate business investment in the United States, The United States is the world's largest biopharmaceutical market, accounting for almost a third of worldwide salesand the world's leader in biopharmaceutical research and development.

According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2019, American companies invested around USD 83 billion in R&D activities, which accounts for more than half of all world's pharmaceutical R&D investment, and own the intellectual property rights to the majority of most new drugs. The United States offers one of the most favorable domestic environments in the world for pharmaceutical development and commercialization, with few market obstacles. Supportive domestic environment and sophisticated biopharmaceutical and pharmaceutical sector are favoring to contribute the biggest share to the single-use assemblies market.

Competitive Landscape

The single-use assemblies market is highly fragmented and consists of many major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Avantor Inc, GE Healthcare, Parker Hannifin Corporation, and Saint-Gobain.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Companies Mentioned
 
Thermo Fisher Scientific
Sartorius AG
Danaher Corporation
Merck KGaA
Avantor
Lonza
GE Healthcare
Parker Hannifin Corporation
Saint
Gobain
Repligen Corporation
NewAge Industries
Corning Incorporated
Entegris
Antylia Scientific
Charter Medical

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.